NFG
RGLS

Next Financial Group’s Regulus Therapeutics RGLS Stock Holding History

Next Financial Group’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5
Closed – – 2351
2019
Q4 		$0 Hold
5
– – ﹤0.01% 2509
2019
Q3 		$0 Hold
5
– – ﹤0.01% 2399
2019
Q2 		$0 Hold
5
– – ﹤0.01% 2375
2019
Q1 		$0 Hold
5
– – ﹤0.01% 2027
2018
Q4 		$0 Hold
5
– – ﹤0.01% 2080
2018
Q3 		$0 Buy
+5
New +$165 ﹤0.01% 1515

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Next Financial Group's RGLS Position: Q1 2020 in Review

Next Financial Group sold out of Regulus Therapeutics (RGLS) in Q1 2020, closing a stake of 5 shares.

Next Financial Group first reported a position in RGLS in Q3 2018 and held it in 6 quarters. The position peaked at $0 in Q4 2019. 28 funds tracked by Wall St. Rank hold RGLS as of Q1 2020.

  • Next Financial Group reported no remaining Regulus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Next Financial Group sold 5 Regulus Therapeutics shares in Q1 2020.
  • Next Financial Group first reported a position in Regulus Therapeutics in Q3 2018 and held it in 6 quarters.
  • Next Financial Group's Regulus Therapeutics position peaked at $0 in Q4 2019.
  • 28 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2020.

Based on Next Financial Group's 13F filing for Q1 2020, filed 27 Apr 2020.